New Chinese medicines and formula granules prop up the market of over 100 billion yuan, and the pharmaceutical machinery industry is expected to receive "bonus"

At present, the entire Chinese medicine industry has ushered in high-quality development with the support of favorable national and local policies.
The new Chinese medicines and formula granules in the sub-sector are considered by the industry to have great potential and promising prospects.
It is expected that these tracks will be in the future It is expected to support a market exceeding 100 billion yuan
.
In this context, the upstream pharmaceutical equipment industry will also usher in opportunities, and related equipment companies are expected to enjoy "bonus"
.
Medicine machines and equipment (Photo source: PharmaNet) Speeding up the evaluation of new Chinese medicines In recent years, the evaluation of new Chinese medicines has accelerated significantly
.
Statistics show that from 2016 to 2020, 13 new traditional Chinese medicines were approved for marketing, and in 2021, a total of 12 new traditional Chinese medicines were launched, setting a new high in the number of approvals in the past five years
.
Entering 2022, the innovative vitality of traditional Chinese medicine is still being released.
It was reported on January 10 that the 1.
2 class innovative drug icariin soft capsule has recently been approved by the State Food and Drug Administration for marketing
.
This is the first innovative traditional Chinese medicine drug approved for marketing in China in 2022
.
In addition, Yunnan Baiyao announced on March 3 that the company received approval from the State Food and Drug Administration to conduct clinical trials of the company's new class 1 traditional Chinese medicine, Quansanqi Tablets, for chest tightness and heartache caused by blood stasis
.
According to industry forecasts, in the next few years, more than 12 new Chinese medicines will be approved for listing each year
.
It is foreseeable that the market for innovative Chinese medicines will be quite active in the future
.
Compared with traditional Chinese medicine decoction pieces, Chinese medicine formula granules are more convenient to take and carry, and are in line with the fast-paced life>
.
With the completion of the pilot work of traditional Chinese medicine formula granules in November 2021, the scope of application of formula granules will be expanded from "Traditional Chinese medicine hospitals above second-level hospitals" to all medical institutions, which means that the number of enterprises entering this field may continue to increase in the future, and the tens of billions of formula granules market Expansion will be accelerated
.
Many institutions predict that the market size of traditional Chinese medicine formula granules will approach 100 billion yuan in 2030
.
Facing the huge blue ocean of the market, more than 30 listed companies, including Tasly, Jilin Aodong, Yiling Pharmaceutical, Panlong Pharmaceutical, Kunyao Group, Zhenbaodao Pharmaceutical, Zuoli Pharmaceutical, etc.
, have clearly laid out traditional Chinese medicine formula granules.

.
On February 8, Jilin Aodong announced that its holding subsidiary, Yanbian Pharmaceutical, had received 8 national standards for the "Listing Certificates of Chinese Medicine Formula Granules".
"
.
Yiling Pharmaceutical recently stated on the interactive platform that the current production and sales of the company's traditional Chinese medicine formula granules business is normal
.
In the future, the company will continue to actively expand the market sales of traditional Chinese medicine formula granules business
.
It is reported that the formula granule business is a business segment in the traditional Chinese medicine sector of Ling Pharmaceutical.
The company has completed the research and development of more than 180 formula granules in accordance with the new national standards, and has made production records
.
The industry believes that compared with new entrants, the first-enterprise enterprises in the formula granule market have obvious barriers and may benefit in the future
.
At present, some companies have achieved performance growth
.
For example, on January 28, Hongri Pharmaceutical released its annual performance forecast for 2021.
It is expected that the company's net profit in 2021 will be 631 million to 746 million yuan, an increase of 10.
05% to 30.
10% over the same period last year
.
Regarding the reasons for the growth in performance, the company stated that during the reporting period, the company's traditional Chinese medicine formula granules business continued to strengthen the national production capacity layout, and continued to improve market coverage and stock market penetration
.
The pharmaceutical machinery industry is expected to benefit from the "bonus".
New Chinese medicines and formula granules will support a market of over 100 billion in the future.
At the same time, it is also expected to bring opportunities to the upstream "shovel sellers", that is, the Chinese medicine pharmaceutical equipment industry.
to "bonus"
.
Taking the upstream equipment of traditional Chinese medicine formula granules as an example, the "Announcement on Ending the Pilot Work of Traditional Chinese Medicine Formula Granules" clarifies that enterprises should have the complete production capacity of traditional Chinese medicine processing, extraction, separation, concentration, drying, and granulation
.
This also means that companies entering the bureau may drive the growth in demand for related production equipment such as traditional Chinese medicine processing, extraction, and drying. .
It is worth mentioning that while the pharmaceutical machinery industry sees opportunities, it also needs to consider the challenges it faces
.
At present, the traditional and backward pharmaceutical processes and equipment can no longer meet the requirements of modern pharmaceuticals.
Pharmaceutical companies are accelerating their development towards automation and intelligence, and the automation requirements for equipment are higher
.
Under this trend, pharmaceutical machine companies need to seize the new market demand and continuously innovate and upgrade equipment, such as considering the concept of intelligent manufacturing in the design of pharmaceutical processes, improving the production efficiency of equipment, reducing error rates, reducing costs, and promoting the high growth rate of the traditional Chinese medicine industry.
Quality development
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.